Research Reports

Summary

Sana Biotechnology, Inc. announced the appointment of Brian Piper as Executive Vice President, Chief Financial Officer, and Treasurer effective February 17, 2026, succeeding Steven D. Harr, M.D., as Principal Financial Officer. Mr. Piper's offer letter provides a $515,000 base salary, 40% target bonus, options for 900,000 shares, and 200,000 RSUs.

Key takeaways

Brian Piper appointed Executive Vice President, Chief Financial Officer, and Treasurer on 2026-02-17
Steven D. Harr ceased serving as acting Principal Financial Officer immediately prior to 2026-02-17
Annual base salary of $515,000 with target annual bonus of 40%
Option to purchase 900,000 shares of common stock; 200,000 RSUs granted under 2021 Incentive Award Plan
Prior CFO roles at Scorpion Therapeutics, Antares Therapeutics, Prelude Therapeutics, and Aevi Genomic Medicine
No family relationships or disclosable transactions with Company per Item 404(a)